Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

ClinicalTrials.gov ID: NCT02960217

Public ClinicalTrials.gov record NCT02960217. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

Study identification

NCT ID
NCT02960217
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Enrollment
44 participants

Conditions and interventions

Interventions

  • UX007 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
6 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 18, 2017
Primary completion
Oct 8, 2019
Completion
Oct 8, 2019
Last update posted
Jun 15, 2020

2017 – 2019

United States locations

U.S. sites
4
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
Colorado Children's Hospital Aurora Colorado 80045
Nicklaus Children's Hospital Miami Florida 33155
Center for Rare Neurological Diseases Norcross Georgia 30093
Columbia University Medical Center New York New York 10032

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02960217, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 15, 2020 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02960217 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →